Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF SYH2072 TABLETS FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION AND RESISTANT HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial (SYH2072–003) of SYH2072 Tablets (the "**Product**") developed by the Group for the treatment of uncontrolled hypertension and resistant hypertension, has been officially initiated at the first centre in China.

The Product is a Class 1 chemical drug and a highly selective, potent aldosterone synthase inhibitor ("**ASI**"). It can inhibit the activity of the key enzyme in aldosterone synthesis (CYP11B2), block the synthesis and secretion of aldosterone by the zona glomerulosa cells of the adrenal cortex, reduce circulating aldosterone levels, and alleviate sodium and water retention, thereby lowering blood pressure and mitigating hypertension-related target organ damage.

Compared with other aldosterone-modulating agents such as mineralocorticoid receptor antagonist (MRA), highly selective ASIs block aldosterone synthesis at its source, effectively reducing plasma aldosterone levels and avoiding aldosterone escape associated with long-term administration. Non-clinical studies showed that the Product demonstrated clear target-specific activity and antihypertensive effects with a favourable safety profile, which is expected to provide a new therapeutic option for patients.

The Group received the Notice of Approval for Clinical Trial of Drug from the National Medical Products Administration of the People's Republic of China in December 2025, and initiated the Phase I clinical trial following the approval. The safety and pharmacokinetic/pharmacodynamic profiles of the Product in humans have been preliminarily verified, indicating its potential to bring cardiovascular benefits to the hypertensive population in China.

The clinical trial initiated this time is a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy and safety of the Product in patients with uncontrolled hypertension (including those with resistant hypertension) who have received treatment with two or more antihypertensive medications. Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 3 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.